GOLDEN, Colo. — July 11, 2023 – PharmaJet®, a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery today announced that Nanette Cocero, Ph.D., has been appointed to its Board of Directors. Dr. Cocero is a recognized leader in the global pharmaceutical industry with broad
View
GOLDEN, Colo. — June 6, 2023 – PharmaJet® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery today announced that Marie Mazur, PharmD, has been appointed Chair of the Board of Directors. She replaces Ron Lowy who had chaired the Board since 2011.
View
GOLDEN, Colo. — May 2, 2023 – PharmaJet ® a company engineering Precision Delivery Systems™ that may overcome the challenges of vaccines and pharmaceuticals delivery today announced that Nathalie Landry, has been appointed Chief Scientific Officer.
View
GOLDEN, Colo. — May 10, 2022 — PharmaJet ®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that Darin Zehrung has joined the executive leadership team as Chief Business Development Officer. Mr. Zehrung is a
View
GOLDEN, Colo. — February 1, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that Chris Cappello, President and CEO of PharmaJet was featured in CEOCFO Magazine.
View
GOLDEN, Colo. — March 17, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding
View
GOLDEN, Colo. — Feb. 20, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine, a leading biotherapeutics company headquartered in South Korea, for the development and commercialization of DNA vaccines for human applications using the PharmaJet needle-free injection systems.
View
GOLDEN, Colo. – Feb. 22, 2013 – PharmaJet Inc. has entered into a collaboration agreement with CureVac GmbH for delivery of CureVac’s mRNA-based vaccine portfolio including targets in oncology and infectious diseases, using the PharmaJet needle-free jet injector platform.
View
GOLDEN, Colo. – March 22, 2011 – The U.S. Food and Drug Administration (FDA) has awarded PharmaJet 510(k) clearance to market a 0.1mL Intradermal (ID) Needle-free Injection System.
View
Load more